Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam, Mohammed; Mangia, Alessandra; Berg, Thomas; Chan, Henry Lik Yuen; Irving, William L; Dore, Gregory J; Abate, Maria Lorena; Bugianesi, Elisabetta; Adams, Leon A; Najim, Mustafa A M; Miele, Luca; Weltman, Martin; Mollison, Lindsay; Cheng, Wendy; Riordan, Stephen; Fischer, Janett; Romero-Gomez, Manuel; Spengler, Ulrich; Nattermann, Jacob; Rahme, Antony; Sheridan, David; Booth, David R; McLeod, Duncan; Powell, Elizabeth; Liddle, Christopher; Douglas, Mark W; van der Poorten, David; George, Jacob.
; 64(1): 34-46, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26822232
Interferon lambda 4 rs368234815 TT>Î´G variant is associated with liver damage in patients with nonalcoholic fatty liver disease.
Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD).
Non-alcoholic fatty liver disease.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease.
Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD.
Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance.
Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.